中国实用内科杂志2025，Vol.45Issue(3)：216-226,11.DOI:10.19538/j.nk2025030108
黄葵胶囊治疗慢性肾脏病临床应用专家共识
Expert consensus on the clinical application of Huang Kui Capsules in the treatment of chronic kidney disease
摘要
Abstract
The global prevalence of chronic kidney disease(CKD)has risen in recent years,which affects approximately 8.2％of the population in China.Traditional Chinese medicine plays a significant role in CKD treatment.Huang Kui Capsules are classified as a Category Ⅲ new traditional Chinese medicine,having the effects of clearing damp-heat,detoxifying,and reducing swelling,and have been widely used in the treatment of CKD since their introduction to the market.This consensus systematically sorts out the current clinical researches on Huang Kui Capsules,integrating practitioners'experiences in clinical application and adhering to the principles of"evidence-based medicine being primary,consensus being supplemental,and experience being a reference."Utilizing the Delphi method and nominal group technique,seven recommendations and suggestions have been developed,which outline the indications,target populations,dosage,combination therapy,precautions,adverse reactions,and preventions and management of adverse reactions of Huang Kui Capsules.The goal is to standardize the clinical drug use,reduce the risks,increase the efficacy,and improve patients'outcomes.This consensus serves as a reference for clinicians in traditional Chinese and Western medicine across various medical institutions in the rational use of Huang Kui Capsules.关键词
黄葵胶囊/慢性肾脏病/专家共识/临床应用/中成药Key words
Huang Kui Capsules/chronic kidney disease/expert consensus/clinical application/Chinese patent drug分类
医药卫生引用本文复制引用
中华中医药学会肾病分会,黄葵胶囊治疗慢性肾脏病临床应用专家共识项目组,杨洪涛..黄葵胶囊治疗慢性肾脏病临床应用专家共识[J].中国实用内科杂志,2025,45(3):216-226,11.基金项目
天津市南开区中医药传承创新发展示范试点项目(20240206004) （20240206004）
